Coronavirus company news summary - MeMed receives CE mark for test to predict disease severity - iXensor introduces data management platform for antigen test - Verdict Medical Devices
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Coronavirus company news summary – MeMed receives CE mark for test to predict disease severity – iXensor introduces data management platform for antigen test

28 Jul 2021

MeMed has secured the European CE mark for its MeMed COVID-19 Severity test, which uses host response technology to check for various proteins in a serum sample. The test uses machine learning to then predict the risk of severe outcomes in patients with Covid-19. It reads the immune system in real-time to offer precise results within 15 minutes.

iXensor has launched the new PixoHealth Pass Admin App and Web Portal screening solution for Covid-19. The platform is designed for use with the PixoTest POCT COVID-19 Antigen Test, which identifies the main SARS-CoV-2 variants such as Delta, Gamma, Alpha and Beta. The new solution screens and validates the Covid-19 linked health conditions using a QR code scan shown by PixoHealth Pass App users. It simultaneously coordinates relevant health data and rapid test results from the app users and PixoTest POCT Analyzer.

Malaysian telemedicine firm DOC2US has launched the RTKis Rapid Test Kit Intelligent System for testing, recording, management and reporting of Covid-19 cases. The system comprises an RTK antigen test kit for self-testing at home. The test result is validated by artificial intelligence technology on the DOC2US RTKis platform. The system currently works with the Gmate Saliva Antigen Test Kit, which is imported by CityMedics.